REPL Replimune Group, Inc. Full Business Value

Replimune Group, Inc. (REPL) develops Immulytic oncolytic viruses while awaiting the results of final-stage melanoma trials. Progress is accelerating through AI modeling and automation, although physicians remain indispensable. The lack of stable revenue leaves the company dependent on external capital. This chart of the current share price on GURU.Markets, standing at 1091.56, confirms a stage of active R&D investment in the absence of mature products.

REPL (Replimune Group, Inc.) Total Company Value history from 11/23/2025 to 10/27/2026

Replimune Group, Inc. - analytical breakdowns and key metrics (REPL)

- price and consensus price forecast:

Market Price Replimune Group Inc|REPL - Price Target Chart

- market capitalization data:

Market Valuation Replimune|REPL - Total Company Value

- book capitalization data:

Net Assets per Single Share Replimune|REPL - Company Book Value|Market-to-Book Ratio replimune.com|REPL - Aggregate Company Assets

- debt and liquidity data:

Debt to Equity Ratio Replimune Group, Inc.|REPL - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio replimune.com|REPL - Company Debts|Debts to Book Value Replimune

Fundamental valuation:Replimune Group Inc (REPL)

Replimune Group, Inc. (REPL) utilizes outsourcing in clinical trials to minimize capital expenditures, making the historical enterprise value chart a key tool for assessing resource management efficiency. This metric determines the actual acquisition price of the business by summing market capitalization and net debt, allowing investors to distinguish the company's organic growth from balance sheet expansion driven by borrowed funds.

Competitors of Replimune Group, Inc. (REPL)

ImmunityBio Inc - Total Enterprise Value|Total Company Value Immunocore PLC|JANX: Full Business Value|Arcus Biosciences, Inc. (RCUS) - Total Company Value|ZYME (zymeworks.com) - Total Company Value|Total Company Value TNGX (Tango Therapeutics, Inc.)|Total Enterprise Value IOVA|Total Company Value Immatics Corp IMTX|Business Value Xencor Inc. (XNCR)|Compass Therapeutics - Enterprise Value|lyell.com - Real Price to Acquire Entire Company|IPHA (Innate Pharma) - Total Company Value|PYXS: Total Enterprise Value|cgen.com (CGEN) - Total Company Value|IOBT (IO Biotech Inc.) - Total Company Value|Total Company Value STRO (Sutro Biopharma, Inc.)|Total Enterprise Value minktherapeutics.com|HOWL: Enterprise Value|Full Takeover Company Value immixbio.com IMMX|ALXO: Real Price to Acquire Entire Company|CUE - Total Enterprise Value|Real Price to Acquire Entire Company PDS Biotechnology Corp (PDSB)|SONN - Value Adjusted for Debt and Cash|MAIA Biotechnology, Inc. - Enterprise Value|LIMN (Liminatus Pharma Inc.) - Company Buyout Price|Total Company Value LVTX|Real Price to Acquire Entire Company NXTC|Total Company Value LPTX (Leap Therapeutics, Inc.)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Real Price to Acquire Entire Company SNSE (Sensei Biotherapeutics, Inc.)|Theriva Biologics Inc - Enterprise Value|Gritstone Bio (GRTS) - Total Company Value|KA: Business Value|Total Company Value NEXI|Total Enterprise Value Turnstone Biologics Corp.|Vaccinex - Real Price to Acquire Entire Company|Full Takeover Company Value Harpoon Therapeutics Inc (HARP)